Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Cancer. 2014 Apr 15;120(15):2325–2333. doi: 10.1002/cncr.28669

Figure 4.

Figure 4

A 2-factor score for estimating the risk of gastrointestinal stromal tumor (GIST) recurrence during and after adjuvant imatinib based on tumor mitotic count and site. (A) Kaplan-Meier plots show the influence of the score on recurrence-free survival (lowest risk, gastric GIST with ≤10 mitoses per 50 high-power fields of the microscope or nongastric GIST with ≤5 mitoses; intermediate high risk, gastric GIST with 11 to 50 mitoses or nongastric GIST with 6 to 20 mitoses; highest risk, gastric GIST with > 50 mitoses or nongastric GIST with > 20 mitoses per 50 high-power fields). (B) Influence of the predictive groups on recurrence-free survival stratified by the duration of adjuvant imatinib administered. (C) Kaplan-Meier plots show the influence of the score on recurrence-free survival in the ACOSOG Z9001 cohort.